Certara, Inc. (NASDAQ:CERT) Receives $12.58 Average Price Target from Brokerages

Certara, Inc. (NASDAQ:CERT) has been assigned an average rating of “Moderate Buy” from the seventeen brokerages that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, eight have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $12.5833.

A number of equities analysts have weighed in on CERT shares. KeyCorp decreased their price target on Certara from $13.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday, January 8th. Stephens decreased their target price on shares of Certara from $15.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, December 12th. Redburn Partners set a $10.00 price target on shares of Certara in a report on Friday, November 21st. Barclays dropped their price target on shares of Certara from $14.00 to $13.00 and set an “overweight” rating on the stock in a research note on Monday, December 15th. Finally, Leerink Partners raised shares of Certara from a “market perform” rating to an “outperform” rating and set a $13.00 price objective for the company in a research report on Tuesday, January 6th.

Certara Price Performance

CERT opened at $9.49 on Friday. Certara has a 52-week low of $8.02 and a 52-week high of $15.69. The company has a 50 day moving average of $8.99 and a two-hundred day moving average of $10.46. The company has a market cap of $1.51 billion, a P/E ratio of 135.57 and a beta of 1.46. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.11 by $0.03. Certara had a return on equity of 5.18% and a net margin of 2.62%.The company had revenue of $104.62 million for the quarter, compared to analyst estimates of $104.53 million. During the same period last year, the company posted $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, analysts expect that Certara will post 0.28 earnings per share for the current year.

Institutional Investors Weigh In On Certara

A number of hedge funds have recently bought and sold shares of the business. Wasatch Advisors LP increased its holdings in Certara by 28.6% during the 3rd quarter. Wasatch Advisors LP now owns 17,398,337 shares of the company’s stock worth $212,608,000 after purchasing an additional 3,865,455 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Certara by 6.4% during the third quarter. Dimensional Fund Advisors LP now owns 8,352,281 shares of the company’s stock worth $102,064,000 after buying an additional 499,523 shares in the last quarter. Deerfield Management Company L.P. increased its stake in shares of Certara by 71.7% in the third quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock worth $82,357,000 after buying an additional 2,813,438 shares during the last quarter. Geneva Capital Management LLC raised its holdings in Certara by 0.7% in the third quarter. Geneva Capital Management LLC now owns 6,160,754 shares of the company’s stock valued at $75,284,000 after acquiring an additional 45,859 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in Certara by 25.3% in the second quarter. Teacher Retirement System of Texas now owns 5,674,485 shares of the company’s stock valued at $66,391,000 after acquiring an additional 1,145,554 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.